New Amsterdam Pharma
Biotechnology, 215 Church St, New Haven, Connecticut, 06510, United States, 11-50 Employees
Phone Number: +31**********
Who is NEWAMSTERDAM PHARMA
Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to impro...
Read More
-
Headquarters: 215 Church St, New Haven, Connecticut, 06510, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from NEWAMSTERDAM PHARMA
NewAmsterdam Pharma Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NewAmsterdam Pharma
Answer: NewAmsterdam Pharma's headquarters are located at 215 Church St, New Haven, Connecticut, 06510, United States
Answer: NewAmsterdam Pharma's phone number is +31**********
Answer: NewAmsterdam Pharma's official website is https://newamsterdampharma.com
Answer: NewAmsterdam Pharma's revenue is $50 Million to $100 Million
Answer: NewAmsterdam Pharma's SIC: 2834
Answer: NewAmsterdam Pharma's NAICS: 325412
Answer: NewAmsterdam Pharma has 11-50 employees
Answer: NewAmsterdam Pharma is in Biotechnology
Answer: NewAmsterdam Pharma contact info: Phone number: +31********** Website: https://newamsterdampharma.com
Answer: Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating Obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy. In January 2021, NewAmsterdam completed its Series A funding round of $196M (160M) which will support the full Phase 3 development of Obicetrapib.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month